Efficacy and Tolerability of Clarema 1% Cream and Hirudoid 40000 U.APTT Gel in the Topical Treatment of Haematomas and/or Subcutaneous Haematic Extravasations

Table 1

Demographic and baseline clinical characteristics. If not otherwise stated, entries are mean and 95% CI.

	Heparan sulfate	GAGPS
Demographic characteristics
Gender (𝑛-%):
males	30 (41.7%)	21 (43.8%)
females	28 (58.3%)	27 (56.3%)
Age (years)	41.9 (37.4 to 46.5)	38.3 (34.0 to 42.6)
Weight (kg)	70.9 (67.5 to 74.4)	69.8 (66.7 to 72.9)
Height (cm)	172.4 (170.0 to 174.8)	172.5 (169.7 to 175.3)
BMI (cm/m^2)	23.8 (22.9 to 24.7)	23.4 (22.6 to 24.3)
Baseline subjective symptoms and objective signs
Pain at rest	1.3 (1.1 to 1.4)	1.2 (1.0 to 1.3)
Pain at movement	2.3 (2.1 to 2.4)	2.3 (2.2 to 2.5)
Functional disability	2.1 (2.0 to 2.3)	2.3 (2.1 to 2.5)
Oedema	2.4 (2.2 to 2.6)	2.5 (2.3 to 2.6)
Colour of the lesion	3.0 (3.0 to 3.0)	3.0 (2.9 to 3.0)
Total score	11.1 (10.6 to 11.6)	11.2 (10.8 to 11.7)
Size of haematomas/extravasation at baseline
Minimum diameter (cm)	5.7 (5.1 to 6.3)	6.0 (5.4 to 6.7)
Maximum diameter (cm)	8.8 (8.1 to 9.6)	9.0 (8.1 to 9.9)
Min*Max diameter (cm^2)	53.9 (44.4 to 63.4)	60.0 (44.0 to 76.1)